CCDC33 Inhibitors
CCDC33 inhibitors are a class of chemical compounds that specifically target the CCDC33 (Coiled-Coil Domain-Containing 33) protein, a member of the coiled-coil domain-containing family. CCDC33 is involved in protein-protein interactions and is thought to play a role in organizing cellular structures and facilitating intracellular signaling. Proteins with coiled-coil domains are known for their ability to mediate the assembly of larger protein complexes due to their structural versatility and their role in maintaining the architecture of various cellular components. Inhibitors of CCDC33 act by interfering with its ability to form these interactions, potentially disrupting the function of protein complexes that rely on CCDC33 as a scaffold or regulatory component.
The inhibition of CCDC33 can have widespread effects on cellular organization, particularly in processes where protein-protein interactions are crucial, such as signal transduction, vesicle transport, or cytoskeletal dynamics. CCDC33 is believed to participate in molecular complexes that control cell structure and function, and inhibitors that target this protein may impair the stability and efficiency of these complexes. This disruption can lead to alterations in cellular processes like protein trafficking, cellular communication, or the maintenance of structural integrity. By blocking CCDC33, these inhibitors serve as important tools for investigating the specific molecular mechanisms involving coiled-coil domain proteins and their role in maintaining cellular homeostasis. The selective inhibition of CCDC33 allows researchers to explore its specific contributions to intracellular signaling pathways and the broader implications of coiled-coil proteins in cellular architecture and function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that can inhibit a broad spectrum of kinases, which may include those that phosphorylate CCDC33, potentially reducing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that can downregulate PI3K/Akt signaling. Since this pathway can be involved in multiple cellular processes, including those that may modulate CCDC33, its inhibition can result in decreased function of CCDC33. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress the mTOR signaling pathway. Given that mTOR can regulate protein synthesis, inhibiting it could decrease the functional activity of CCDC33 through reduced protein translation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that could disrupt signaling pathways that may cross-talk with those regulating CCDC33, thereby potentially inhibiting CCDC33 activity indirectly. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that can prevent the activation of the PI3K/Akt pathway, potentially diminishing the functional activity of CCDC33 if it is regulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A specific inhibitor of MEK, which acts upstream of MAPK/ERK. By inhibiting this, PD98059 may indirectly decrease CCDC33 activity if it is influenced by the MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, part of the MAPK signaling pathways. Inhibiting JNK could indirectly reduce CCDC33 activity if there is pathway integration. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that impedes the function of the Rho/Rho-kinase pathway, which might be indirectly involved in regulating CCDC33 function, thereby potentially inhibiting it. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can affect the degradation process of proteins. If CCDC33 is subject to proteasomal degradation, bortezomib could increase CCDC33 levels, but might also affect its functional state by altering protein turnover. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
An inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), potentially disrupting calcium homeostasis. If CCDC33's function is calcium-dependent, this disruption could lead to its inhibition. | ||||||